Development of a new antibody drug to treat congenital tooth agenesis.

Congenital tooth agenesis Tooth regeneration USAG-1 neutralizing antibody Wnt10A

Journal

Journal of oral biosciences
ISSN: 1880-3865
Titre abrégé: J Oral Biosci
Pays: Netherlands
ID NLM: 101226721

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 17 08 2024
revised: 04 10 2024
accepted: 07 10 2024
medline: 11 10 2024
pubmed: 11 10 2024
entrez: 10 10 2024
Statut: aheadofprint

Résumé

This study aimed to develop a therapeutic agent promoting teeth regeneration from autologous tissues for congenital tooth agenesis, specifically for hypodontia (≤ 5 missing congenital teeth, 10% prevalence) and oligodontia (≥ 6 missing congenital teeth, 0.1% prevalence). We studied mice genetically deficient in the USAG-1 protein, an antagonist of BMP/Wnt which forms excessive teeth. We identified USAG-1 as a target molecule for increasing the number of teeth. Crossing USAG-1-deficient mice with a congenital tooth agenesis model restored tooth formation. We produced anti-USAG-1 neutralizing antibodies as potential therapeutic agents for the treatment of congenital tooth agenesis. Mice anti-USAG-1 neutralizing antibodies can potentially rescue the developmentally arrested tooth germ programmed to a certain tooth type. A humanized anti-USAG-1 antibody was developed as the final candidate. Targeting USAG-1 shows promise for treating missing congenital tooth. Anti-USAG-1 neutralizing antibodies have been developed and will progress towards clinical trials, which may regenerate missing congenital teeth in conditions, such as hypodontia and oligodontia. The protocol framework for a phase 1 study has been finalized, and preparation for future studies is underway.

Sections du résumé

BACKGROUND BACKGROUND
This study aimed to develop a therapeutic agent promoting teeth regeneration from autologous tissues for congenital tooth agenesis, specifically for hypodontia (≤ 5 missing congenital teeth, 10% prevalence) and oligodontia (≥ 6 missing congenital teeth, 0.1% prevalence).
HIGHLIGHT CONCLUSIONS
We studied mice genetically deficient in the USAG-1 protein, an antagonist of BMP/Wnt which forms excessive teeth. We identified USAG-1 as a target molecule for increasing the number of teeth. Crossing USAG-1-deficient mice with a congenital tooth agenesis model restored tooth formation. We produced anti-USAG-1 neutralizing antibodies as potential therapeutic agents for the treatment of congenital tooth agenesis. Mice anti-USAG-1 neutralizing antibodies can potentially rescue the developmentally arrested tooth germ programmed to a certain tooth type. A humanized anti-USAG-1 antibody was developed as the final candidate.
CONCLUSION CONCLUSIONS
Targeting USAG-1 shows promise for treating missing congenital tooth. Anti-USAG-1 neutralizing antibodies have been developed and will progress towards clinical trials, which may regenerate missing congenital teeth in conditions, such as hypodontia and oligodontia. The protocol framework for a phase 1 study has been finalized, and preparation for future studies is underway.

Identifiants

pubmed: 39389160
pii: S1349-0079(24)00204-4
doi: 10.1016/j.job.2024.10.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

K Takahashi (K)

Dentistry & Oral Surgery, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan; Toregem Toregem BioPharma, Co.,Ltd, Kyoto, Japan. Electronic address: katsu-takahashi@kitano-hp.or.jp.

H Kiso (H)

Toregem Toregem BioPharma, Co.,Ltd, Kyoto, Japan.

E Mihara (E)

Laboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka, Japan.

J Takagi (J)

Laboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka, Japan.

Y Tokita (Y)

Department of Disease model, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Aichi, Japan.

A Murashima-Suginami (A)

Dentistry & Oral Surgery, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan; Toregem Toregem BioPharma, Co.,Ltd, Kyoto, Japan.

Classifications MeSH